DERMATOLOGICAL THERAPEUTIC MARKET ANALYSIS

Dermatological Therapeutic Market, By Application (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, Acne Vulgaris, Vitiligo, Hidradenitis, and Other Applications), By Drug Class (Anti-infectives, Corticosteroids, Calcineurin Inhibitors, Retinoids, and Other Drug Classes), By Geography (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023
Code : CMI5490
Pages :164
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Dermatological Therapeutic Market: Key Developments

In July 2020, Concert Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for the company’s oral janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata.

In March 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) granted the breakthrough therapy designation to Baricitinib for the treatment of alopecia areata.

In February 2020, Almirall and Paratek entered into a License Agreement for Seysara (sarecycline) in China, It is a once-daily, oral tetracycline-derived antibiotic with anti-inflammatory properties for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

In February 2019, Maruho and Asahi Kasei Pharma announced that Asahi Kasei Pharma obtained a partial change of approval for anti-herpes virus agent "Famvir Tab 250 mg" (famciclovir) for the treatment of recurrent herpes simplex (herpes labialis/herpes genitalis) in Japan.